Company / Cost of Revenue
West Pharmaceutical Services Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$2.0B
FY2025
5-year range
$1.2B / $2.0B
FY2021-FY2025
Trend
+4.0%
vs FY2024
Sector context
#29 of 113
Health Care
What the data says
At $2.0B, West Pharmaceutical Services's cost of revenue ranks #85 of 113 in the Health Care sector. Cost of Revenue has increased for 5 consecutive years, from $1.2B in FY2020 to $2.0B in FY2025.
Based on SEC 10-K filings.
$2.0B in FY2025 with a 5-year CAGR of +10.9%. Top quartile in the Health Care sector.
Increased from $1.8B to $2.0B over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +12.6%
- 5-Year CAGR
- +10.9%
- 10-Year CAGR
- -
Sector benchmark
#85 of 113 in Health CareTop 74% of 113This company $2.0B Sector average $11.3B
▼
-82.6% below sector average
Key checks
Key Insights
- West Pharmaceutical Services's cost of revenue has grown for 5 consecutive years.
- 5-year CAGR of +10.9%, indicating consistent growth.
- In FY2025, cost of revenue increased 4.0% year-over-year.
- Ranks #29 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.0B | +4.0% |
| FY2024 | $1.9B | +4.1% |
| FY2023 | $1.8B | +32.0% |
| FY2022 | $1.4B | +11.7% |
| FY2021 | $1.2B | +5.3% |
| FY2020 | $1.2B | -5.0% |
| FY2019 | $1.2B | +5.3% |
| FY2018 | $1.2B | +7.9% |
| FY2017 | $1.1B | +11.6% |
| FY2016 | $973.6M | +4.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026